Treatment of cryptosporidiosis in immunocompromised hosts: Still an open question

Chemotherapy

Volumn 51, Issue 4, 2005, Pages 193-196

  Zardi, E M ^a   Picardi, A ^a   Afeltra, A ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Antiretroviral therapy; Cryptosporidiosis; Immunocompromised patients; Protease inhibitors

Indexed keywords

ASPARTIC PROTEINASE; ATOVAQUONE; AZITHROMYCIN; CLARITHROMYCIN; ENZYME INHIBITOR; INDINAVIR; LASALOCID; LETRAZURIL; MONOCLONAL ANTIBODY; NITAZOXANIDE; OCTREOTIDE; PAROMOMYCIN; POLYCLONAL ANTIBODY; PROTEINASE INHIBITOR; ROXITHROMYCIN; SPIRAMYCIN;

ARTICLE; CLINICAL TRIAL; CRYPTOSPORIDIOSIS; CRYPTOSPORIDIUM; CRYPTOSPORIDIUM HOMINIS; CRYPTOSPORIDIUM PARVUM; DIARRHEA; DRUG ABSORPTION; DRUG EFFICACY; ENTERITIS; ENZYME ASSAY; ENZYME INHIBITION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOST CELL; HOST PARASITE INTERACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE DEFICIENCY; IMMUNOTHERAPY; LIFE CYCLE; LOW DRUG DOSE; META ANALYSIS; NONHUMAN; PARASITE; PREVALENCE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME;

ANIMALS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ASPARTIC ENDOPEPTIDASES; CRYPTOSPORIDIOSIS; CRYPTOSPORIDIUM PARVUM; HIV INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; PROTEASE INHIBITORS;

EID: 26044442857     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000086920     Document Type: Article

References (5)

1. Chen XM, LaRusso NF: Mechanisms of attachment and internalization of Cryptosporidium parvum to biliary and intestinal epithelial cells. Gastroenterology 2000;118:368-379.
2. Amadi B, Mwiya M, Musuku J, Watuka A, Sianongo S, Ayoub A, Kelly P: Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: A randomised controlled trial. Lancet 2002;360:1375-1380.
3. Ives NJ, Gazzard BG, Easterbrook PJ: The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART) in a London clinic. J Infect 2001;42:134-139.
4. Smith K, Aga E, Bosch RJ, Valdez H, Connick E, Landay A, Kuritzkes D, Gross BH, Francis IR, McCune JM, Kessler H, Lederman M: Long-term changes in circulating CD4 T lymphocytes in virologically suppressed patients after 6 years of highly active antiretro viral therapy. AIDS 2004;18:1953-1956.
5. Dupuis ML, Tombesi M, Sabatini M, Cianfriglia M: Differential effect of HIV-1 protease inhibitors on P-glycoprotein function in multidrug-resistant variants of the human CD4+ T lymphoblastoid CEM cell line. Chemotherapy 2003;49:8-16.